meta
|
Preg
- medecines during pregnancy KB
Search
Topiramate (Epilepsy)
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Morrow (Topiramate) (Controls unexposed, sick), 2006 Ornoy (Topiramate), 2008 Mawer (Topiramate) (Controls unexposed, sick), 2010 Hernández-Díaz (Topiramate), 2012 Veiby (Topiramate) (Controls unexposed, sick), 2014 Tomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2019 Meador (Topiramate) (Controls unexposed, sick), 2020 Thomas (Topiramate) (Controls unexposed, sick), 2021
9
2.06
[
1.34
; 3.17]
229
323
not evaluable
Major congenital malformations
Morrow (Topiramate) (Controls unexposed, sick), 2006 Ornoy (Topiramate), 2008 Mawer (Topiramate) (Controls unexposed, sick), 2010 Hernández-Díaz (Topiramate), 2012 Veiby (Topiramate) (Controls unexposed, sick), 2014 Tomson (Topiramate), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2019 Meador (Topiramate) (Controls unexposed, sick), 2020 Thomas (Topiramate) (Controls unexposed, sick), 2021
9
2.06
[
1.34
; 3.17]
229
323
not evaluable
Congenital heart defects
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Vajda (Topiramate) (Controls unexposed, sick), 2013 Tomson (Topiramate), 2018 Thomas (Topiramate) (Controls unexposed, sick), 2021
4
2.75
[
0.99
; 7.59]
32
233
not evaluable
Limb defects
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Vajda (Topiramate) (Controls unexposed, sick), 2013 Thomas (Topiramate) (Controls unexposed, sick), 2021
3
3.56
[
0.59
; 21.68]
5
81
not evaluable
Neural Tube Defects
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Vajda (Topiramate) (Controls unexposed, sick), 2013 Tomson (Topiramate), 2018
3
5.56
[
0.78
; 39.78]
2
224
not evaluable
Digestive system anomalies
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Thomas (Topiramate) (Controls unexposed, sick), 2021
2
6.26
[
0.69
; 56.84]
4
37
not evaluable
Urinary malformations
Tomson (Topiramate), 2018 Thomas (Topiramate) (Controls unexposed, sick), 2021
2
1.68
[
0.22
; 13.11]
14
161
not evaluable
Hypospadias
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Tomson (Topiramate), 2018
2
3.30
[
0.73
; 14.97]
14
180
not evaluable
Nervous system anomalies
Thomas (Topiramate) (Controls unexposed, sick), 2021
1
39.94
[
0.75
; 2134.65]
-
9
not evaluable
Oro-facial clefts
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 Tomson (Topiramate), 2018
2
7.95
[
0.83
; 76.53]
5
180
not evaluable
Spina bifida
Veiby (Topiramate) (Controls unexposed, sick), 2014
1
12.67
[
0.64
; 249.11]
3
43
not evaluable
Cleft lip with or without cleft palate
Vajda (Topiramate) (Controls unexposed, sick), 2013
1
3.37
[
0.07
; 172.23]
-
44
not evaluable
Polydactyly
Tomson (Topiramate), 2018
1
16.59
[
0.33
; 839.05]
-
152
not evaluable
Growth parameters and prematurity
Small for gestational age (weight)
Hernández-Díaz (Topiramate), 2017 Cohen (Topiramate) (Controls unexposed NOS), 2019 Dreier (Topiramate), 2021
3
1.79
[
1.19
; 2.72]
41,644
611
not evaluable
Preterm (< 37 weeks)
Arkilo (Topiramate), 2015 Cohen (Topiramate) (Controls unexposed NOS), 2019
2
0.75
[
0.49
; 1.16]
160,598
2
not evaluable
Maternal consequences
Abruptio placentae (retroplacental hematoma)
Cohen (Topiramate) (Controls unexposed NOS), 2019
1
0.82
[
0.21
; 3.18]
20,260
-
not evaluable
Preeclampsia
Cohen (Topiramate) (Controls unexposed NOS), 2019
1
1.23
[
0.63
; 2.41]
53,625
-
not evaluable
Long term consequences
Emotional disorders
Bromley (Topiramate), 2016 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
2
0.92
[
0.43
; 1.97]
466
317
not evaluable
Behavioral disorders
Bromley (Topiramate), 2016
1
0.84
[
0.36
; 1.94]
-
27
not evaluable
Intrauterine deaths
Intrauterine deaths (as a whole or unspecified)
Arkilo (Topiramate), 2015 Trivedi (Topiramate) (Controls unexposed, sick), 2018 Vajda (Topiramate) (Controls unexposed, sick), 2018 Meador (Topiramate) (Controls unexposed, sick), 2020
4
9.39
[
2.18
; 40.53]
14
70
not evaluable
Late intrauterine deaths (> 22 weeks)
Arkilo (Topiramate), 2015 AlSheikh (Topiramate) (Controls unexposed, sick), 2020
2
15.37
[
0.63
; 376.77]
-
3
not evaluable
Early intrauterine death (< 22 weeks)
Babic (Topiramate), 2014 Arkilo (Topiramate), 2015
2
8.47
[
0.57
; 125.19]
3
4
not evaluable
Neuro-developmental disorders
ASD (Autism spectrum disorder): Diagnosis/Risk
Wood (Topiramate), 2015 Bjørk (Topiramate) (Controls unexposed, sick), 2018 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
3
2.00
[
1.02
; 3.91]
359
297
not evaluable
Language disorders/delay
Bromley (Topiramate), 2016 Husebye (Topiramate) (Controls unexposed, sick), 2020 Meador (Topiramate) (Controls unexposed, disease free), 2021
3
1.76
[
0.63
; 4.86]
43
36
not evaluable
ASD (Autism spectrum disorder): Risk
Wood (Topiramate), 2015 Bjørk (Topiramate) (Controls unexposed, sick), 2018
2
2.65
[
0.36
; 19.38]
28
7
not evaluable
Neuro-developmental disorders (as a whole)
Arkilo (Topiramate), 2015 Bjørk (Topiramate) (Controls unexposed, sick), 2022
2
2.15
[
1.15
; 4.01]
455
248
not evaluable
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk
Bromley (Topiramate), 2016 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
2
1.64
[
0.71
; 3.81]
544
317
not evaluable
ASD (Autism spectrum disorder): Diagnosis
Wood (Topiramate), 2015 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
2
2.02
[
1.00
; 4.08]
331
291
not evaluable
Cognitive developmental disorders/delay (> 6 years old)
Bromley (Topiramate), 2016 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
2
2.22
[
1.00
; 4.91]
195
317
not evaluable
ADHD (Attention deficit hyperactivity disorder): Diagnosis
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
1
2.38
[
1.40
; 4.05]
544
290
not evaluable
Severe cognitive developmental delay (Mental retardation) (> 6 years old)
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023
1
2.23
[
0.90
; 5.51]
189
290
not evaluable
ADHD (Attention deficit hyperactivity disorder): Risk
Bromley (Topiramate), 2016
1
1.00
[
0.43
; 2.32]
-
27
not evaluable
0.0
100.0
1.0